Holmium-166 Radioembolization Physics

Holmium-166 radioembolization is a liver-directed therapy whose defining feature is that the particle which treats the tumor can also be seen. Ho-166 pairs a therapeutic beta emission with an imageable gamma line and paramagnetic behavior, so the identical microsphere is quantifiable by SPECT, CT, and MRI — at scout scale before treatment and at therapeutic scale afterward. That closes the loop between planning, delivery, and verification in a way a pure beta emitter cannot.⁸⁹

Introduction

Transarterial radioembolization delivers a radioactive microsphere through the hepatic artery so that it lodges preferentially in the hypervascular tumor bed and irradiates the tumor from within. For two decades the workhorse isotope has been yttrium-90, a nearly pure beta emitter. It works, but it has a blind spot: because Y-90 emits almost no imageable photons, the work-up relies on a surrogate particle, technetium-99m macroaggregated albumin, and post-treatment verification depends on faint bremsstrahlung or a very small positron branch.⁹¹⁰

Holmium-166 was developed to remove that blind spot. Loaded into poly-L-lactic acid microspheres, Ho-166 is a beta emitter for therapy, a gamma emitter for SPECT, and paramagnetic for MRI — all in one particle. The consequence is that the same holmium microsphere can be given as a small scout dose to predict distribution, delivered as therapy, and then imaged to compute the absorbed dose that was actually deposited.⁸⁹¹⁴

This guide explains the decay physics that makes holmium distinctive, the scout-dose work-up, the personalized dosimetry targets, how the delivered dose is quantified, and how Ho-166 compares with Y-90. DRPS supports these programs through its PET/CT and nuclear medicine physics and medical physics consulting services across Florida, Maryland, Virginia, Washington DC, California, and Nevada.

Topic Explanation

The microsphere and the delivery

Holmium-166 radioembolization uses poly-L-lactic acid (PLLA) microspheres with a mean diameter of about 30 micrometers — small enough to pass into and lodge within the tumor microvasculature, but too large to pass through it into the systemic circulation. Holmium is incorporated into the polymer at roughly one-fifth of the sphere mass and is neutron-activated to produce Ho-166.⁸⁹

The microspheres are injected through a catheter placed in the hepatic artery. Because liver tumors draw most of their blood supply from the hepatic artery while normal parenchyma is supplied mainly by the portal vein, the particles concentrate in the tumor bed. Once lodged, they are permanently retained and decay in place, so the effective half-life equals the physical half-life. For the surrogate-particle work-up that this approach improves upon, see our guide to Tc-99m MAA lung shunt fraction in Y-90 therapy.

Why holmium is a theranostic particle

The word that best describes Ho-166 is theranostic: the same agent supports both therapy and diagnosis. Three properties combine to make this possible:

• Therapeutic beta emission deposits a large, local absorbed dose in the tumor.
• An imageable 80.6 keV gamma escapes the patient and is detected by a gamma camera, enabling quantitative SPECT/CT.
• Paramagnetism produces a measurable MRI signal, enabling MRI-based dosimetry.⁸⁹¹²

This is a different model from Y-90, where the therapeutic particle and the diagnostic surrogate are two different materials. For the broader context of matched therapy-imaging pairs, see common PET and RPT isotopes and our overview of MIRD-schema internal dosimetry.

Key Technical Principles

Ho-166 decay physics

Holmium-166 decays by beta-minus emission to stable erbium-166, with a half-life of about 26.8 hours. The beta spectrum has a maximum energy near 1.85 MeV and a mean energy of approximately 0.67 MeV, giving a maximum range in soft tissue of roughly 8.7 mm and a mean range near 2.2 mm — so most of the dose is deposited within about 2 mm of each microsphere. A small fraction of decays, on the order of 6 to 7 percent, produce the 80.6 keV gamma used for imaging.¹⁸⁹

Holmium-166 versus yttrium-90

Both isotopes deliver therapy by beta emission, but their imaging and work-up characteristics differ substantially.

The practical upshot: holmium's shorter half-life delivers dose faster, and its imageable gamma and paramagnetism make the same particle its own diagnostic agent, at both scout and therapeutic scale.⁸⁹¹⁰ Comparisons should be read as indirect — there is no randomized head-to-head trial of Ho-166 against Y-90 — but the imaging advantages of holmium are physical, not merely clinical.

The absorbed-dose calculation

Radioembolization dosimetry follows the MIRD framework. For a permanently retained beta emitter whose energy is deposited locally, the mean absorbed dose to a target region is the total number of decays multiplied by the mean energy per decay, divided by the target mass:

where $\tilde{A}$ is the time-integrated activity (total decays). Because the microspheres are permanently trapped and decay in place, $\tilde{A}=A_0/\lambda =1.443\cdot T_{1/2}\cdot A_0$. Substituting holmium's mean beta energy $\bar{E}\approx 0.67\text{MeV}=1.07\times 10^{-13}\text{J}$ and $T_{1/2}=26.8\text{h}$ gives a convenient per-activity constant:

As a worked example, delivering 4 GBq of Ho-166 into a treated lobe of mass 1.5 kg yields:

This is a whole-compartment average; the real value of holmium is that post-treatment SPECT or MRI replaces this single number with a voxel-level dose map, revealing how dose is actually distributed between tumor and parenchyma.⁵⁷¹²

Clinical Impact

The scout dose changes the work-up

Before the therapeutic administration, a small scout dose — approximately 250 MBq of Ho-166 microspheres — is delivered and imaged. Because the scout is the same particle as the treatment, it predicts three things that matter: the lung shunt fraction, the intrahepatic distribution, and any extrahepatic deposition. Published work found that the Ho-166 scout predicts the lung mean dose more accurately than the traditional Tc-99m MAA surrogate, which tends to overestimate lung dose.¹¹¹⁴

A better lung-dose prediction is not academic: overestimating lung shunt can wrongly disqualify a patient or force a dose reduction, while underestimating it risks radiation pneumonitis. Using the identical particle for prediction removes a layer of surrogate uncertainty.

Personalized, verifiable dosimetry

Holmium's imageability supports a plan-deliver-verify cycle. Dosimetry is personalized rather than a fixed activity: published dose-response analyses in colorectal liver metastases associate tumor mean absorbed doses above roughly 90 Gy with improved outcomes, while healthy liver parenchyma is generally kept below about 55 Gy, and lung dose is capped at 30 Gy per treatment.⁵⁶ Higher tumor doses have been linked to better response in hepatocellular carcinoma as well.⁷

After treatment, SPECT/CT or MRI produces a voxel-level absorbed-dose map that confirms whether the tumor received its intended dose and whether parenchyma and lung stayed within limits. This verification is the practical payoff of choosing an imageable therapeutic particle. For the general principles, see radiopharmaceutical dosimetry and ICRP 128.

Quantitative imaging is not automatic

The therapeutic administration puts a large activity of holmium in the liver, and quantitative SPECT at high count rates requires deliberate gamma-camera characterization — energy-window selection around the 80.6 keV line, scatter correction, and count-rate and dead-time handling. A camera setup validated for Tc-99m at 140 keV cannot be assumed to quantify holmium correctly. Programs should validate the holmium quantification protocol as part of commissioning.¹³

Practical Optimization Tips

A defensible holmium radioembolization program follows a consistent physics workflow.

1. Commission the imaging before the therapy

Validate the SPECT/CT quantification protocol for Ho-166 at clinically relevant activities: energy window, scatter and attenuation correction, calibration factor, and dead-time behavior. Establish the MRI-based dosimetry pathway if it will be used.

2. Use the scout to plan, not just to screen

Treat the scout distribution as the basis for the personalized activity prescription — lung shunt, tumor-to-normal ratio, and any extrahepatic uptake — not merely as a safety check.

3. Prescribe to dose, cap the organs at risk

Convert the plan into an activity that targets the intended tumor dose while keeping parenchyma below its threshold and lung below 30 Gy. Document the assumptions: treated mass, segmentation, and the dose model used.

4. Verify with post-treatment imaging

Compute the delivered voxel dose map from post-therapy SPECT/CT or MRI. Compare tumor coverage and organ-at-risk dose against the plan, and record the comparison — this is both quality assurance and defensible documentation.

Common pitfalls to avoid

• Assuming a Tc-99m camera setup quantifies holmium. The 80.6 keV line and high activity demand a validated protocol.
• Treating dosimetry as a fixed activity. Personalized planning to tumor and organ-at-risk doses is the point of an imageable particle.
• Skipping post-treatment verification. The delivered dose map is holmium's key advantage; not using it wastes the isotope's main benefit.
• Copying Y-90 lung-shunt assumptions. The Ho-166 scout predicts lung dose differently — and generally better — than Tc-99m MAA.
• Overlooking supply and regulatory status. Availability and approval status have changed over time and must be confirmed for the jurisdiction.

Regulatory Considerations

Holmium-166 is a reactor-produced byproduct material, so its medical use is governed by the NRC or an Agreement State under the medical-use framework, and the therapy must be integrated into the facility's radioactive material license. Because Ho-166 microspheres are a therapeutic use of byproduct material, the program falls under written-directive, authorized-user, and patient-management requirements.

Key frameworks to reference:

• 10 CFR Part 35 — Medical Use of Byproduct Material, governing authorized users, written directives, and the handling of therapeutic radiopharmaceuticals.
• 10 CFR Part 20 — Standards for Protection Against Radiation, setting occupational and public dose limits that shape handling, shielding, and release practices.
• NRC NUREG-1556, Volume 9 — program-specific guidance for medical-use licenses, relevant when amending a license to add a new therapy.
• EANM procedure guideline for intra-arterial radioactive compounds (2022) — the European professional guidance covering both Ho-166 and Y-90 and the personalized-dosimetry expectation.¹⁰
• ICRP Publication 107 — the nuclear decay-data reference underlying dose and shielding calculations.¹

Regulatory status differs by jurisdiction. Holmium-166 microspheres are CE-marked in Europe but are not FDA-approved in the United States, where their use has been investigational; commercial availability has also changed over time. Of the states DRPS serves, Florida, Maryland, Virginia, California, Nevada, Pennsylvania, New York, and New Jersey are NRC Agreement States that license medical use under their own radiation-control rules, while Washington, DC and Delaware are regulated directly by the NRC. A facility must confirm the current approval and supply status of the product and coordinate any new therapy with license amendments, authorized-user credentialing, and its dosimetry program. Connect this review to radioactive material license support and medical physics consulting, and see the radiation-safety companion, Y-90 radioembolization radiation safety.

Frequently Asked Questions (FAQs)

What is holmium-166 radioembolization?

It is a transarterial liver-directed therapy in which poly-L-lactic acid microspheres loaded with holmium-166 are delivered through the hepatic artery to lodge in the tumor microvasculature. Ho-166 emits therapeutic beta particles that deposit dose locally, plus a low-energy gamma line and paramagnetic signal that allow the same microspheres to be imaged and quantified by SPECT, CT, and MRI.

How is Ho-166 different from Y-90 for radioembolization?

Yttrium-90 is essentially a pure beta emitter that can only be imaged indirectly by bremsstrahlung SPECT or by its tiny positron branch on PET, and its work-up uses a surrogate particle, Tc-99m MAA. Holmium-166 adds an imageable 80.6 keV gamma and is paramagnetic, so it is directly quantifiable, and the same holmium microspheres are used at scout and therapeutic scale. Ho-166 also has a shorter half-life of about 26.8 hours.

What is the Ho-166 scout dose?

The scout dose is a small activity of holmium-166 microspheres, on the order of 250 megabecquerels, given before the therapeutic administration to predict where the particles will distribute. Because the scout uses the same microsphere as the treatment, it predicts lung shunting and intra- and extrahepatic distribution more faithfully than a Tc-99m MAA surrogate.

What absorbed doses are targeted in Ho-166 radioembolization?

Dosimetry is personalized rather than fixed. Published dose-response work in colorectal liver metastases associates tumor mean absorbed doses above roughly 90 gray with better outcomes, while healthy liver parenchyma is generally kept below about 55 gray and lung dose is capped at 30 gray per treatment. Exact prescriptions depend on tumor burden, liver reserve, and the segmentation of the treated volume.

How is the delivered Ho-166 dose measured after treatment?

Because holmium-166 emits an imageable gamma and is paramagnetic, post-treatment SPECT/CT or MRI is used to map where the microspheres actually landed and to compute a voxel-level absorbed-dose distribution. This verification step is a major advantage of holmium over pure beta emitters, since it confirms tumor coverage and checks parenchyma and lung dose against the plan.

Why does the low-energy gamma of Ho-166 matter for imaging?

The 80.6 keV gamma emission, present in roughly 6 to 7 percent of decays, is energetic enough to escape the patient and be detected by a gamma camera, enabling quantitative SPECT/CT. High activities require careful gamma-camera setup because of count-rate and scatter effects, which is why quantification protocols must be validated for holmium rather than assumed from a standard Tc-99m setup.

Is holmium-166 radioembolization approved in the United States?

Holmium-166 microspheres are CE-marked in Europe but are not FDA-approved in the United States, where their use has been investigational. Regulatory status and commercial availability have changed over time, so any facility considering the therapy should confirm the current approval and supply status and align its radioactive material license and dosimetry program accordingly.

Key Takeaways

• Holmium is a theranostic particle. One microsphere provides therapeutic beta dose, an imageable 80.6 keV gamma, and paramagnetic MRI signal.
• The scout dose uses the same particle. A ~250 MBq Ho-166 scout predicts lung shunt and distribution more faithfully than a Tc-99m MAA surrogate.
• Dose deposits locally. With a mean beta range near 2 mm, most energy is deposited within about 2 mm of each microsphere.
• Dosimetry is personalized and verifiable. Tumor doses above ~90 Gy are associated with better outcomes in mCRC, with parenchyma kept below ~55 Gy and lung below 30 Gy.
• Quantification must be commissioned. High-activity Ho-166 SPECT needs a validated protocol, not a Tc-99m setup.
• Confirm status by jurisdiction. CE-marked in Europe, investigational in the US, with availability that has changed over time.

Conclusion

Holmium-166 radioembolization is a clear illustration of why imageable therapy particles matter. By combining a therapeutic beta emission with an imageable gamma and paramagnetism, holmium lets a program plan with the real particle, deliver it, and then verify the absorbed dose it actually produced. That plan-deliver-verify loop turns radioembolization from a fixed-activity procedure into a personalized, documented, dosimetry-driven treatment.

For the medical physicist, holmium's advantages come with responsibilities: commission the quantitative imaging, build the personalized dosimetry workflow, and verify delivery against the plan. Facilities that treat the imageability as a tool to be validated and used — rather than a feature to be assumed — will get the full benefit of the isotope while keeping the program defensible under the medical-use license.

How DRPS Can Help

Diagnostic Radiation Physics Services supports nuclear medicine and interventional programs that deliver radioembolization. This may include PET/CT and nuclear medicine physics support, SPECT/CT quantification commissioning and validation, personalized-dosimetry workflow design, post-treatment dose verification review, radioactive material license support for adding a new therapy, and medical physics consulting aligned with NRC and Agreement State requirements.

DRPS supports facilities across our service locations, including Florida, Maryland, Virginia, Washington DC, California, Nevada, New York, Pennsylvania, New Jersey, and Delaware.

A strong radioembolization program does not just deliver activity — it plans to a dose, verifies what was delivered, and documents both.

Related Resources

• Y-90 radioembolization dosimetry
• Tc-99m MAA lung shunt fraction for Y-90
• Y-90 PET radioembolization imaging
• MIRD-schema internal dosimetry
• Radiopharmaceutical dosimetry and ICRP 128
• Y-90 radioembolization radiation safety
• PET/CT and nuclear medicine physics
• Radioactive material license support

References

1. International Commission on Radiological Protection. ICRP Publication 107: Nuclear Decay Data for Dosimetric Calculations. Annals of the ICRP. 2008;38(3). icrp.org
2. Smits MLJ, Nijsen JFW, van den Bosch MAAJ, et al. Holmium-166 radioembolisation in patients with unresectable, chemorefractory liver metastases (HEPAR trial): a phase 1, dose-escalation study. Lancet Oncol. 2012;13(10):1025-1034. doi:10.1016/S1470-2045(12)70334-0. PubMed
3. Prince JF, van den Bosch MAAJ, Nijsen JFW, et al. Efficacy of radioembolization with 166Ho-microspheres in salvage patients with liver metastases: a phase 2 study. J Nucl Med. 2018;59(4):582-588. doi:10.2967/jnumed.117.197194. PubMed
4. Braat AJAT, Bruijnen RCG, van Rooij R, et al. Additional holmium-166 radioembolisation after lutetium-177-dotatate in patients with neuroendocrine tumour liver metastases (HEPAR PLuS): a single-centre, single-arm, open-label, phase 2 study. Lancet Oncol. 2020;21(4):561-570. doi:10.1016/S1470-2045(20)30027-9. PubMed
5. Bastiaannet R, van Roekel C, Smits MLJ, et al. First evidence for a dose-response relationship in patients treated with 166Ho radioembolization: a prospective study. J Nucl Med. 2020;61(4):608-612. doi:10.2967/jnumed.119.232751. PubMed
6. van Roekel C, Bastiaannet R, Smits MLJ, et al. Dose-effect relationships of 166Ho radioembolization in colorectal cancer. J Nucl Med. 2021;62(2):272-279. doi:10.2967/jnumed.120.243832. PubMed
7. Reinders MTM, Braat AJAT, van Erpecum KJ, et al. Holmium-166 radioembolisation dosimetry in hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2025;52(3):993-1003. doi:10.1007/s00259-024-06940-2. PubMed
8. Reinders MTM, Smits MLJ, van Roekel C, Braat AJAT. Holmium-166 microsphere radioembolization of hepatic malignancies. Semin Nucl Med. 2019;49(3):237-243. doi:10.1053/j.semnuclmed.2019.01.008. PubMed
9. Stella M, Braat AJAT, van Rooij R, de Jong HWAM, Lam MGEH. Holmium-166 radioembolization: current status and future prospective. Cardiovasc Intervent Radiol. 2022;45(11):1634-1645. doi:10.1007/s00270-022-03187-y. PubMed
10. Weber M, Lam M, Chiesa C, et al. EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. Eur J Nucl Med Mol Imaging. 2022;49(5):1682-1699. doi:10.1007/s00259-021-05600-z. PubMed
11. Wagemans MEHM, Braat AJAT, van Rooij R, et al. Lung mean dose prediction in transarterial radioembolization: superiority of [166Ho]-scout over [99mTc]MAA in a prospective cohort study. Cardiovasc Intervent Radiol. 2024;47(4):443-450. doi:10.1007/s00270-023-03656-y. PubMed
12. Roosen J, van Wijk MWM, Westlund Gotby LEL, et al. Improving MRI-based dosimetry for holmium-166 transarterial radioembolization using a nonrigid image registration for voxelwise calculation. Med Phys. 2023;50(2):935-946. doi:10.1002/mp.16014. PubMed
13. Stella M, Braat AJAT, Lam MGEH, de Jong HWAM, van Rooij R. Gamma camera characterization at high holmium-166 activity in liver radioembolization. EJNMMI Phys. 2021;8(1):22. doi:10.1186/s40658-021-00372-9. PubMed
14. Braat AJAT, Prince JF, van Rooij R, Bruijnen RCG, van den Bosch MAAJ, Lam MGEH. Safety analysis of holmium-166 microsphere scout dose imaging during radioembolisation work-up: a cohort study. Eur Radiol. 2018;28(3):920-928. doi:10.1007/s00330-017-4998-2. PubMed